Running clinical trials during an active outbreak raises ethical dilemmas. Critically analyse this with reference to recent Ebola vaccine trials in the DRC.

In an active outbreak, research ethics must weigh urgency (saving lives now) against rigour (knowing what works). The 2026 Bundibugyo Ebola outbreak in the DRC makes this tension sharp, because nearly half of confirmed patients die (crude fatality ratio 48.3%) [1]. Trials there are justified, but they come with real dilemmas.

Why trials during an outbreak are ethically justified

• Genuine uncertainty: Ervebo is licensed only for the Zaire virus. WHO experts called the evidence that it protects against other species "limited and inconclusive" [2]. When the benefit is unknown, testing is more ethical than guessing.
• Avoiding false security: WHO allowed Ervebo to be used only within research protocols and called for a ring randomised controlled trial [3]. If people wrongly believe a vaccine works, they may stop isolating and skip safe burials.
• Preparing for the next outbreak: The Tumaini Phase 2/3 trial of Bundibugyo-specific vaccine candidates began in Bunia on 23 October [1]. Without such data, the next outbreak starts from zero.

Ethical dilemmas

• Access vs evidence: Nearly half of confirmed patients die. Anyone placed in a comparison group, or made to wait, may miss out on protection.
• Blurred line between research and access: Of the 70,000 Ervebo doses, 50,000 went to frontline workers and only 20,000 to the trial [4]. This is practical, but it weakens the evidence.
• Consent under pressure: In Ituri and North Kivu, conflict, displacement and distrust of outside authorities [5] make free, informed consent hard to obtain.
• Delay costs lives: Tumaini began more than five months after the outbreak was declared, by which time deaths had reached 4,687 [1]. The leading candidate needed 7–9 months just to be ready for a trial [2].
• Justice: Communities that bear the risks of research must get first access to whatever proves effective.

Overall, trials during an outbreak are ethically defensible when the evidence is truly uncertain, as with Bundibugyo. They must, however, run alongside good care, community trust and fair access. The way forward lies in pre-approved trial protocols, vaccine candidates for all Ebola species prepared before outbreaks begin, and early community engagement. Done this way, "test first" need not mean "wait while people die", and research advances SDG 3's promise of health for all.